Novadaq Technologies to Host Third Quarter Earnings Webcast Live on Tuesday, October 22, 2013

Accesswire

TORONTO, ONTARIO - (ACCESSWIRE - October 21, 2013) - Novadaq Technologies Inc. (NVDQ) will host a live webcast to discuss the results of the third quarter, to be held Tuesday, October 22, 2013 at 8:30 a.m. Eastern Time.

To participate in this event, dial (877) 407-8031 domestically, or (201) 689-8031 internationally, approximately 5 to 10 minutes before the beginning of the call. Additionally, you can listen to the event online at http://www.investorcalendar.com/IC/CEPage.asp?ID=171765.

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=171765 or http://www.investorcalendar.com/, as well as via the Novadaq web site (http://www.novadaq.com/). A podcast of the event will also be available after the webcast.

About Novadaq Technologies Inc.

Enabling medical professionals with clinically-relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is Novadaq's global mission. SPY[R] fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 80 peer-reviewed publications demonstrate that the use of SPY imaging during complex surgery, leads to fewer post-operative complications and lower hospital costs.

SPY Imaging Systems are United States Food and Drug Administration 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT[R], combines the capabilities of SPY Imaging with high definition ("HD") visible light visualization offered by conventional endoscopes. LUNA[TM] is used to assess perfusion in patients being treated for non-healing wounds. In August 2013, Novadaq acquired the surgical scintigraphy imaging technology, which is being developed for perioperative imaging of sentinel lymph nodes and tumor margins. Our unique business model of partnering with market-leading companies to drive adoption of our imaging technology, while building our own commercial infrastructure, is the cornerstone of our corporate strategy for growth.

SOURCE: ACCESSWIRE

Rates

View Comments (0)